Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
19.05. | Immunome stock rating cut to Hold by Boral Capital | 2 | Investing.com | ||
IMMUNOME Aktie jetzt für 0€ handeln | |||||
12.05. | Immunome GAAP EPS of -$0.52 beats by $0.14, revenue of $2.93M beats by $2.47M | 1 | Seeking Alpha | ||
12.05. | Immunome Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.05. | Immunome Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | Hedge Fund and Insider Trading News: Michael Hintze, Stanley Druckenmiller, Bill Ackman, Eisler Capital, Immunome Inc (IMNM), and More | 3 | Insider Monkey | ||
26.03. | Immunome stock rises after insider purchase | 1 | Seeking Alpha | ||
20.03. | Immunome stock target cut to $25 by Guggenheim | 1 | Investing.com | ||
19.03. | Immunome Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
19.03. | Immunome GAAP EPS of -$5.00 misses by $0.62, revenue of $9.04M misses by $0.37M | 1 | Seeking Alpha | ||
19.03. | Immunome Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
19.03. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
30.01. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
30.01. | Immunome-Aktie stürzt nach Preisfestsetzung für öffentliches Angebot ab | 4 | Investing.com Deutsch | ||
30.01. | Immunome stock tumbles after public offering pricing | 1 | Investing.com | ||
29.01. | Immunome plans to commence underwritten public offering | 4 | Seeking Alpha | ||
29.01. | Immunome kündigt Aktienemission im Wert von 125 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
29.01. | Immunome announces $125 million stock offering | 4 | Investing.com | ||
23.01. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
13.11.24 | Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update | 176 | Business Wire | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 27,305 | -2,45 % | Tesla und Moderna: Das sind die Short-Kandidaten von JPMorgan | © Foto: DALL*ETesla und Moderna gehören zu den Aktien, bei denen JPMorgan im zweiten Halbjahr 2025 zu Short-Positionen rät.Zum Start ins zweite Halbjahr ließ Pedro Martins Junior, Co-Leiter der US-Aktienanalyse... ► Artikel lesen | |
CRISPR THERAPEUTICS | 56,00 | 0,00 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
TEMPUS AI | 52,50 | 0,00 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer | ||
OCULAR THERAPEUTIX | 9,780 | +0,41 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
CORCEPT THERAPEUTICS | 61,02 | +0,13 % | Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer | ||
MACROGENICS | 1,318 | +1,46 % | MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results | First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination... ► Artikel lesen | |
ULTRAGENYX | 23,200 | +1,75 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for... ► Artikel lesen | |
AMNEAL PHARMACEUTICALS | 6,800 | -2,16 % | Amneal Pharmaceuticals LLC: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences | Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth... ► Artikel lesen | |
4D MOLECULAR THERAPEUTICS | 4,190 | -3,90 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
EVOTEC | 7,456 | +0,59 % | Bayer, NetraMark, Evotec: Wie KI-Forschung jetzt Renditen beschleunigt und Ihr Depot optimieren könnte | Die Gesundheitsbranche wird 2025 von KI und Technologien radikal umgekrempelt. Während Pharmariesen unter Kostendruck und regulatorischen Stürmen ächzen revolutionieren Algorithmen die Arzneimittelentwicklung:... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings |